Randomized Controlled Trial of Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy Versus Long-Course Chemoradiotherapy in Locally Advanced Rectal Cancer: Comparison of Overall Response Rates

• Published in: Journal of gastrointestinal cancer 2024-03, Vol.55 (1), p.373-382
• Main Authors: Amariyil, Adila, Pathy, Sushmita, Sharma, Atul, Kumar, Sunil, Pramanik, Raja, Bhoriwal, Sandeep, Pandey, R. M.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer Research; Capecitabine - administration & dosage; Capecitabine - therapeutic use; Chemoradiotherapy - methods; Consolidation Chemotherapy - methods; Female; Gastroenterology; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Neoadjuvant Therapy - methods; Oncology; Oxaliplatin - administration & dosage; Oxaliplatin - therapeutic use; Radiotherapy; Rectal Neoplasms - pathology; Rectal Neoplasms - therapy; Treatment Outcome
• ISSN: 1941-6628; 1941-6636
• DOI: 10.1007/s12029-023-00966-9

Background Management of locally advanced rectal cancer (LARC) is evolving with current emphasis on the addition of chemotherapy to short course radiotherapy (SCRT). We primarily aimed to analyse the difference in overall response rates between SCRT with sequential chemotherapy and standard long-course chemoradiotherapy (LCCRT)in LARC. Methods After randomization, patients in arm A received 45 Gy in 25 fractions over 5 weeks with concurrent capecitabine while patients in arm B received 25 Gy in 5 fractions over 1 week followed by 3 cycles of CAPOX (capecitabine and oxaliplatin) chemotherapy. Clinical and radiological response assessment was made after the completion of neoadjuvant treatment, a week prior to surgery. Adjuvant chemotherapy was added to complete 6 months of peri-operative chemotherapy. Surgery was performed between 8 and 10 weeks of completion of radiation treatment in both arms. Results Of the 33 patients recruited in this study between February 2020 to July 2021, 17 patients were randomized to arm A and 16 to arm B. The rates of complete tumour regression were 23.1% in arm A versus 35.7% in arm B ( p -value = 0.683). Pathological complete response (pCR) rate was 20% arm A versus 30% in arm B (0.446). A higher number of patients in arm B experienced grade 3 diarrhoea, whereas acute skin toxicity was seen only in arm A. SCRT had fewer treatment interruptions compared to LCCRT. Conclusions SCRT followed by three cycles of CAPOX chemotherapy in the neoadjuvant setting is comparable to LCCRT in terms of tumour response. This may be a better alternative regimen with fewer treatment interruptions in a resource-limited setting.